Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

884 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials.
Tanizawa Y, Kaku K, Araki E, Tobe K, Terauchi Y, Utsunomiya K, Iwamoto Y, Watada H, Ohtsuka W, Watanabe D, Suganami H; Tofogliflozin 004 and 005 Study group. Tanizawa Y, et al. Among authors: watanabe d. Expert Opin Pharmacother. 2014 Apr;15(6):749-66. doi: 10.1517/14656566.2014.887680. Epub 2014 Feb 11. Expert Opin Pharmacother. 2014. PMID: 24512053 Clinical Trial.
Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study.
Kaku K, Watada H, Iwamoto Y, Utsunomiya K, Terauchi Y, Tobe K, Tanizawa Y, Araki E, Ueda M, Suganami H, Watanabe D; Tofogliflozin 003 Study Group. Kaku K, et al. Among authors: watanabe d. Cardiovasc Diabetol. 2014 Mar 28;13:65. doi: 10.1186/1475-2840-13-65. Cardiovasc Diabetol. 2014. PMID: 24678906 Free PMC article. Clinical Trial.
Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine: A randomized phase IV study (NEXTAGE Study).
Yamada Y, Senda M, Naito Y, Tamura M, Watanabe D, Shuto Y, Urita Y. Yamada Y, et al. Among authors: watanabe d. Diabetes Obes Metab. 2017 Sep;19(9):1252-1259. doi: 10.1111/dom.12945. Epub 2017 Apr 27. Diabetes Obes Metab. 2017. PMID: 28345162 Free PMC article. Clinical Trial.
Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-L randomized clinical trial.
Kaneto H, Takami A, Spranger R, Amano A, Watanabe D, Niemoeller E. Kaneto H, et al. Among authors: watanabe d. Diabetes Obes Metab. 2020 Sep;22 Suppl 4:3-13. doi: 10.1111/dom.14005. Diabetes Obes Metab. 2020. PMID: 32072742 Clinical Trial.
Benefits of the fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide (iGlarLixi) in Japanese people with type 2 diabetes: A subgroup and time-to-control analysis of the LixiLan JP phase 3 trials.
Terauchi Y, Yabe D, Kaneto H, Amano A, Baxter M, Watanabe D, Watada H, Inagaki N. Terauchi Y, et al. Among authors: watanabe d. Diabetes Obes Metab. 2020 Sep;22 Suppl 4:35-47. doi: 10.1111/dom.14139. Diabetes Obes Metab. 2020. PMID: 33404200 Clinical Trial.
Incidence of childhood type 1 diabetes mellitus in Yamanashi Prefecture, Japan, 1986-2018.
Saito T, Kobayashi K, Kobayashi K, Mochizuki M, Yagasaki H, Makino K, Narusawa H, Watanabe D, Mitsui Y, Sato K, Sano T, Ohta M, Yokomichi H, Amemiya S. Saito T, et al. Among authors: watanabe d. Endocrinol Diabetes Metab. 2020 Dec 14;4(2):e00214. doi: 10.1002/edm2.214. eCollection 2021 Apr. Endocrinol Diabetes Metab. 2020. PMID: 33855216 Free PMC article.
884 results